INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment.

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/8773

Files in this item

File Description Format
PDF HOPS_Mortality_ ... revised 30June2011 _1_.pdf (296KB) (no description provided) PDF
Title: Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment.
Author(s): Palella, FJ Jr; Baker, RK; Buchacz, K; Chmiel, JS; Tedaldi, EM; Novak, RM; Durham, MD; Brooks, JT
Subject(s): Comorbidity HIV Infections
Abstract: Objective: Understanding mortality differences among HIV-infected patients can focus efforts to improve survival. Design: We evaluated death rates, causes and associated factors among treated patients in the HOPS, a large, prospective, multicenter observational cohort of HIV-infected persons seen at diverse U.S. sites of care. Methods: Among 3754 HOPS participants seen during 1996-2007 with > 6 months of follow-up after initiating HAART and ≥ 75% of time under observation receiving HAART (“substantially treated”), we calculated hazard ratios for death using proportional hazards regression models, death causes and comorbidities. Results: Substantially treated participants, followed a median 4.7 years (IQR, 2.2-8.5), experienced 331 deaths. In multivariable analyses, higher mortality was associated with index CD4 < 200 counts/mm3 (adjusted hazard ratio [aHR], 2.86; 95% CI, 1.95-4.21), older age (aHR, 1.50 per 10 years; 95% CI, 1.33-1.70), log10HIV RNA (aHR, 1.67 per log10; 95% CI, 1.51-1.85), but not race/ethnicity (aHR, 0.99 for blacks vs whites, p=0.92). Mortality was increased among publicly insured (PUB) vs privately insured participants (PRV ) when index CD4 >200 (aHR, 2.03; 95% CI, 1.32-3.14) but not when index CD4 < 200 cells/mm3 (aHR, 1.3, p=0.13). By death cause, PUB had significantly more cardiovascular events and hepatic disorders than PRV. Comorbidities more frequent among PUB vs PRV decedents included cardiovascular disease, renal impairment and chronic hepatitis. Conclusions: Among HAART treated participants with CD4 ≥ 200 cells/mm3, PUB experienced higher death rates than PRV. Non-AIDS death and disease causes predominated among publicly insured decedents, suggesting that treatable comorbidities contributed to survival disparities.
Issue Date: 2011-09-24
Publisher: Lippincott, Williams & Wilkins
Citation Info: Palella FJ Jr, Baker RK, Buchacz K, Chmiel JS, Tedaldi EM, Novak RM, Durham MD, Brooks JT; HOPS Investigators. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS. 2011 Sep 24;25(15):1865-76. 10.1097/QAD.0b013e32834b3537
Type: Article
Description: Post print version of article may differ from published version. The definitive version is available through Lippincott, Williams & Wilkins at DOI:10.1097/QAD.0b013e32834b3537
URI: http://hdl.handle.net/10027/8773
ISSN: 0269-9370
Sponsor: The HOPS is funded by the Centers for Disease Control and Prevention (CDC, contract no. 200-2006-18797).
Date Available in INDIGO: 2012-11-06
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
United States of America 258
China 25
Japan 20
United Kingdom 17
Germany 11

Browse

My Account

Information

Access Key